Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib.
Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib.
复制标题
DOI：
10.18632/oncotarget.22807
复制
发表时间：
2017-12-15
期刊：
影响因子：
--
通讯作者：
Nakajima TE
中科院分区：
文献类型：
--
作者：
Arai H;Miyakawa K;Denda T;Mizukami T;Horie Y;Izawa N;Hirakawa M;Ogura T;Tsuda T;Sunakawa Y;Nakajima TE
目前尚不清楚早期形态改变(EMC)是否是转移性结直肠癌(MCRC)中瑞格拉非尼的预测标记物。因此，本研究调查EMC是否能预测接受瑞格拉非尼治疗的mCRC患者的预后。这项研究评估了68名患者。52例肺转移瘤中，空洞形成16例(31.0%)。中位无进展生存期(PFS)为4.2/2.4个月(P<0.01)，总生存期(OS)为9.2/6.5个月(P=0.09)。45例肝转移瘤患者中，14例(31%)出现主动形态反应(MR)。有无活动期MR患者的中位PFS和OS分别为5.3/2.4个月(P<0.01)和13.6/6.9个月(P=0.02)。总体而言，25名患者(37%)患有EMC。有无EMC患者的中位PFS和OS分别为5.3/2.1个月(P<；0.01)和13.3/6.1个月(P&t；0.01)。这项回顾性研究包括接受瑞可非尼治疗的肺和/或肝转移的mCRC患者。在第一次治疗后的CT扫描中评估肺转移瘤的CF和肝转移瘤的MR。EMC被确定为CF和/或活动MR。我们比较了有无EMC患者的PFS和OS。EMC可作为预测瑞可非尼治疗多发性结直肠癌的有用指标。
It is unclear whether early morphological change (EMC) is a predictive marker for regorafenib in metastatic colorectal cancer (mCRC). Therefore, the present study investigated whether EMC can predict the outcome of mCRC patients receiving regorafenib. This study evaluated 68 patients. Among 52 patients with lung metastasis, 16 (31%) had cavity formation (CF). The median progression-free survival (PFS) and overall survival (OS) in patients with/without CF were 4.2/2.4 months (p<0.01) and 9.2/6.5 months (p=0.09), respectively. Among 45 patients with liver metastasis, 14 (31%) had active morphological response (MR). The median PFS and OS in patients with/without active MR were 5.3/2.4 months (p<0.01) and 13.6/6.9 months (p=0.02), respectively. Overall, 25 patients (37%) had EMC. The median PFS and OS in patients with/without EMC were 5.3/2.1 months (p<0.01) and 13.3/6.1 months (p<0.01), respectively. This retrospective study included mCRC patients with lung and/or liver metastases receiving regorafenib. CF in lung metastasis and MR in liver metastasis were evaluated at the first post-treatment computed tomography scan. EMC was determined as CF and/or active MR. We compared PFS and OS between patients with and those without EMC. EMC could be a useful predictive marker for regorafenib in mCRC.
登录
查看更多内容
影响因子：
5
作者：
Smith, Andrew Dennis;Lieber, Michael L.;Shah, Shetal N.
通讯作者：
Shah, Shetal N.
影响因子：
120.7
作者：
Chun, Yun Shin;Vauthey, Jean-Nicolas;Boonsirikamchai, Piyaporn;Maru, Dipen M.;Kopetz, Scott;Palavecino, Martin;Curley, Steven A.;Abdalla, Eddie K.;Kaur, Harmeet;Charnsangavej, Chusilp;Loyer, Evelyne M.
通讯作者：
Loyer, Evelyne M.
影响因子：
51.1
作者：
Stintzing, Sebastian;Modest, Dominik P.;Heinemann, Volker
通讯作者：
Heinemann, Volker
使用贝伐单抗治疗的非小细胞肺癌患者的肿瘤空化。
DOI：
10.1102/1470-7330.2012.0027
发表时间：
2012-06-29
期刊：
Cancer imaging : the official publication of the International Cancer Imaging Society
影响因子：
--
作者：
Nishino M;Cryer SK;Okajima Y;Sholl LM;Hatabu H;Rabin MS;Jackman DM;Johnson BE
通讯作者：
Johnson BE
影响因子：
51.1
作者：
Li, Jin;Qin, Shukui;Kim, Tae Won
通讯作者：
Kim, Tae Won